Amisulpride augmentation therapy improves cognitive performance and psychopathology in clozapine-resistant treatment-refractory schizophrenia: a 12-week randomized, double-blind, placebo-controlled trial
Open Access
- 18 October 2022
- journal article
- research article
- Published by Elsevier in Military Medical Research
- Vol. 9 (1) , 1-13
Abstract
Background: Although clozapine is an effective option for treatment-resistant schizophrenia (TRS), there are still 1/3 to 1/2 of TRS patients who do not respond to clozapine. The main purpose of this randomized, double-blind, placebo-controlled trial was to explore the amisulpride augmentation efficacy on the psychopathological symptoms and cognitive function of clozapine-resistant treatment-refractory schizophrenia (CTRS) patients. Methods: A total of 80 patients were recruited and randomly assigned to receive initial clozapine plus amisulpride (amisulpride group) or clozapine plus placebo (placebo group). Positive and Negative Syndrome Scale (PANSS), Scale for the Assessment of Negative Symptoms (SANS), Clinical Global Impression (CGI) scale scores, Repeatable Battery for the Assessment of Neuropsychological Status (RBANS), Treatment Emergent Symptom Scale (TESS), laboratory measurements, and electrocardiograms (ECG) were performed at baseline, at week 6, and week 12. Results: Compared with the placebo group, amisulpride group had a lower PANSS total score, positive subscore, and general psychopathology subscore at week 6 and week 12 ( P Bonferroni < 0.01). Furthermore, compared with the placebo group, the amisulpride group showed an improved RBANS language score at week 12 ( P Bonferroni < 0.001). Amisulpride group had a higher treatment response rate ( P = 0.04), lower scores of CGI severity and CGI efficacy at week 6 and week 12 than placebo group ( P Bonferroni < 0.05). There were no differences between the groups in body mass index (BMI), corrected QT (QTc) intervals, and laboratory measurements. This study demonstrates that amisulpride augmentation therapy can safely improve the psychiatric symptoms and cognitive performance of CTRS patients. Conclusion: This study indicates that amisulpride augmentation therapy has important clinical significance for treating CTRS to improve clinical symptoms and cognitive function with tolerability and safety. Trial registration Clinicaltrials.gov identifier- NCT03652974. Registered August 31, 2018, https://clinicaltrials.gov/ct2/show/NCT03652974Keywords
All Related Versions
Funding Information
- Clinical Research Project of Shanghai Municipal Health (20204Y0173)
- The National Natural Science Foundation of China (81401127)
- Scientific Research Project of Traditional Chinese Medicine of Guangdong (20192070)
- Science and Technology Plan Project of Guangdong Province (2019B030316001)
- Guangzhou Municipal Key Discipline in Medicine (2021-2023)
- State Key Laboratory of Control and Simulation of Power System and Generation Equipment (VRLAB2022 B02)
- Shanghai Key Laboratory of Psychotic Disorders Open Grant (21-K03)
This publication has 69 references indexed in Scilit:
- Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysisThe Lancet, 2013
- Amisulpride promotes cognitive flexibility in rats: The role of 5-HT7 receptorsBehavioural Brain Research, 2013
- 5-HT7R/G12Signaling Regulates Neuronal Morphology and Function in an Age-Dependent MannerJournal of Neuroscience, 2012
- Safety and tolerability of antipsychotics: focus on amisulprideDrug, Healthcare and Patient Safety, 2010
- Amisulpride Augmentation in Patients with Schizophrenia Partially Responsive or Unresponsive to Clozapine. A Randomized, Double-Blind, Placebo-Controlled TrialPharmacopsychiatry, 2008
- Effects of amisulpride on the cognitive function of patients with schizophrenia who switched from risperidoneInternational Journal of Psychiatry in Clinical Practice, 2008
- Defining ‘Response’ in Antipsychotic Drug Trials: Recommendations for the Use of Scale-Derived CutoffsNeuropsychopharmacology, 2007
- Clozapine Alone versus Clozapine and Risperidone with Refractory SchizophreniaNew England Journal of Medicine, 2006
- 5-HT7Receptor Is Coupled to Gα Subunits of Heterotrimeric G12-Protein to Regulate Gene Transcription and Neuronal MorphologyThe Journal of Neuroscience, 2005
- Second-Generation (Atypical) Antipsychotics and Metabolic EffectsCNS Drugs, 2005